Q2 STOCKS TO BUY

2 Biotech Stocks Charging Up the Charts

CymaBay Therapeutics reported upbeat data on its liver disease drug

Managing Editor
Apr 11, 2018 at 10:05 AM
facebook X logo linkedin


Two biotech stocks are making big moves higher this morning, defying the broad-market headwinds related to geopolitical tensions in Syria. Inovio Pharmaceuticals Inc (NASDAQ:INO) scored a critical partnership, while CymaBay Therapeutics Inc (NASDAQ:CBAY) reported upbeat data on its liver disease drug. 

INO Stock Could Benefit From Short Squeeze

The Coalition for Epidemic Preparedness Innovations (CEPI) will award Inovio Pharmaceuticals up to $56 million to advance its DNA vaccines for Lassa fever and MERS. As a result, INO stock is up 3.9% to trade at $4.94, and has rallied 30% from its four-year low of $3.76 on Feb. 9.  However, the shares are still staring up at their 160-day and 200-day moving averages, which have rejected rebound attempts since a bear gap in July 2017.  

A short squeeze is helping fuel the drug stock's rally. Short interest fell by 3.3% during the last reporting period, but the 10.53 million shares sold short still represents more than 12% of INO's total available float. At the equity's average daily trading volume, it would take over a week for the shorts to cover their bearish bets.

CBAY Stock Eyes Best Day Since July

CymaBay Therapeutics stock is up 15.8% to trade at $13.98, on track for its best day since July 2017, after the drugmaker reported a positive mid-stage study update on its liver disease drug, seladelpar. As such, Leerink upped its price target on the equity to $20 from $16 -- representing a premium of 43% to CBAY's current price.

The drug stock touched a record high of $15.59 on March 5, but subsequently pulled back to its 100-day moving average. Today, though, CBAY is set to top its 10- and 20-day trendlines for the first time in more than a month, and sports a year-over-year gain of 233%.

Amid the stock's recent dip, short sellers have piled on. Short interest increased by 11% during the past two reporting periods, to 2.5 million shares. This represents a healthy 8% of CBAY's total available float.
 
 

“Buy This Stock Now!” - Expert Who Called 11x On TSLA

He called a rare 11x on Tesla…

But now, thanks to Elon & Trump’s new alliance…

He says there’s a new opportunity that could be 1,000x BIGGER than Tesla – and it could completely revolutionize a $23 Trillion market.

It’s trading for less than $5 per share right now…

But it won’t be under the radar for long.

Discover The 1,000x Bigger Elon Opportunity Here

GRAND SLAM COUNTDOWN

 
 

Featured Articles from Trusted Partners:

👀Learn How Dividends Create Passive Income for Life
Receive $200 Off Motley Fool Epic. The Motley Fool Epic $299 discounted offer is based on $499/year list price. Introductory promotion for new members only. Take control of your money and your portfolio with Motley Fool Epic.

💵New Income System Could Pay You $4,243 Monthly
You could collect an average of $4,243 per month starting as early as next week with a new payout system for income investors. New registrations are being accepted for investors who want to be in a position to start with their first payout next week.

🚀Easy 92% Crypto Dividends (No Coins Required)
COIN stock doesn't pay a dividend... But there's actually a new way to collect a massive dividend that's indirectly based on the stock and offers a terrific monthly income (currently yielding nearly 92% on a forward basis).

🤝Free Advisor Match with Wiseradvisor.com
Don't leave your retirement to chance! Get matched with a trusted financial expert for FREE and make the most of your tax refund. Get started now.

⚠️Dennis Quaid's #1 Warning for Americans
Here's the thing: life doesn't come with guarantees. The economy shifts, markets stumble, and years of hard work could slip through your fingers like sand. But it doesn't have to be that way for you. So request a free copy of this Gold & Silver Guide that will arrive right to your doorstep when you act now.

 

 
 

Follow us on X, Follow us on Twitter